Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF
Author:
Funder
Boehringer Ingelheim
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine
Reference30 articles.
1. Cardiovascular and renal outcomes with empagliflozin in heart failure;Packer;N Engl J Med,2020
2. Dapagliflozin in patients with heart failure and reduced ejection fraction;McMurray;N Engl J Med,2019
3. Two tales: one story: EMPEROR-Reduced and DAPA-HF;Verma;Circulation,2020
4. The DAPA-HF trial: a momentous victory in the war against heart failure;Bhatt;Cell Metab,2019
5. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-Reduced trial;Anker;Circulation,2021
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared With Monotherapy Improves Long-Term Survival: A Real-World Registry;The American Journal of Medicine;2024-08
2. Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction;Journal of the American College of Cardiology;2024-06
3. How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC;European Journal of Heart Failure;2024-05-22
4. SGLT2 Inhibitors and Diuresis;JACC: Heart Failure;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3